The Food and Drug Administration has approved Womed Leaf®, marking a breakthrough for women suffering from Asherman syndrome, a condition that prevents tens of thousands of American women from becoming pregnant due to intrauterine scarring. The device represents the first FDA-approved medical solution specifically designed to address moderate to severe intrauterine adhesions, a major cause of female infertility.
Revolutionary Approach to Preventing Adhesion Recurrence
Womed Leaf® addresses a critical gap in treating intrauterine adhesions (IUAs), which occur when uterine walls pathologically bind together following surgical procedures. These adhesions develop in 20% to 45% of women undergoing procedures such as dilation and curettage or fibroid removal, leading to infertility, recurrent miscarriages, and pain.
The device consists of a soft thin film made from Womed's innovative polymer technology, inserted like an intrauterine device at the end of an adhesiolysis procedure. Once positioned, it expands within the uterine cavity to prevent contact between the uterine walls during the critical healing phase, then naturally and painlessly discharges from the body.
Clinical Evidence Supports Efficacy
The FDA approval was supported by the pivotal PREG2 randomized clinical study, which enrolled 160 patients with severe or moderate intrauterine adhesions. The study demonstrated that Womed Leaf® significantly reduced the severity of intrauterine adhesion formation after hysteroscopic adhesiolysis compared with no prevention method, while maintaining an acceptable safety profile.
"Asherman syndrome is a condition that prevents tens of thousands of women in the United States from becoming pregnant due to scar tissue in the uterine cavity," said Dr. Keith Isaacson, MD at Audubon Fertility and Ochsner Health System in New Orleans, who has treated over five hundred Asherman patients. "When the adhesions are surgically removed, they often return due to the approximation of the uterine walls, which Womed Leaf will prevent during the healing phase."
Addressing High Recurrence Rates
Current treatment for intrauterine adhesions faces significant challenges, with very high recurrence rates leaving women uncertain and anxious about their chances of conception. The approval of Womed Leaf® offers a new standard of care for this previously underserved patient population.
"This is the first FDA approved barrier for these patients and marks a significant improvement for their ultimate desired outcome," Dr. Isaacson noted, emphasizing the clinical significance of having an approved intervention specifically designed for this indication.
Company Milestone and Future Availability
Gonzague Issenmann, co-founder and CEO of Womed, highlighted the rigorous regulatory process behind the approval. "The meticulous review and inspections performed by the FDA for the PMA are a clear testimony of the rigorous and world-class work that has been accomplished by our team, and makes Womed Leaf the new standard for Asherman syndrome treatment worldwide," he stated.
The company expects Womed Leaf® to become available to American women in early 2026. Womed is developing additional intrauterine treatments based on its proprietary polymer technology platform, with a pipeline including intended treatments for fibroids, endometriosis, and acute uterine bleeding.
